{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:14:45Z","timestamp":1788441285679,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT2037743"],"award-info":[{"award-number":["GNT2037743"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1184428"],"award-info":[{"award-number":["GNT1184428"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Microbe"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.lanmic.2026.101364","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T14:06:48Z","timestamp":1782396408000},"page":"101364","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dual \u03b2-lactam therapy against high-risk Pseudomonas aeruginosa isolates: a dynamic in-vitro infection model study integrating population genomics with quantitative systems pharmacology modelling and simulations"],"prefix":"10.1016","volume":"7","author":[{"given":"Siobhonne K J","family":"Breen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Cort\u00e9s-Lara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica R","family":"Tait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate E","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Leng","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Faith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice E","family":"Terrill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominika T","family":"Fuhs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"L\u00f3pez-Causap\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger L","family":"Nation","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D","family":"Boyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0928-4743","authenticated-orcid":false,"given":"Cornelia B","family":"Landersdorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanmic.2026.101364_bib2","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3389\/fmicb.2018.00685","article-title":"The versatile mutational resistome of Pseudomonas aeruginosa","volume":"9","author":"L\u00f3pez-Causap\u00e9","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.lanmic.2026.101364_bib3","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00031-19","article-title":"Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections","volume":"32","author":"Horcajada","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.lanmic.2026.101364_bib4","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.cmi.2023.12.026","article-title":"Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID\/ISARPAE Group","volume":"30","author":"Oliver","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.lanmic.2026.101364_bib5","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/cid\/ciad758","article-title":"The real crisis in antimicrobial resistance: failure to anticipate and respond","volume":"78","author":"Bonomo","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101364_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106196","article-title":"Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired \u03b2-lactamases: 2020 update","volume":"56","author":"del Barrio-Tofi\u00f1o","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"22","key":"10.1016\/j.lanmic.2026.101364_bib7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.drup.2015.08.002","article-title":"The increasing threat of Pseudomonas aeruginosa high-risk clones","volume":"21","author":"Oliver","year":"2015","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.lanmic.2026.101364_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106368","article-title":"Antibiotic pharmacokinetic\/pharmacodynamic modelling: MIC, pharmacodynamic indices and beyond","volume":"58","author":"Rao","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.lanmic.2026.101364_bib9","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13756-022-01187-8","article-title":"Carbapenem-resistant Pseudomonas aeruginosa: an assessment of frequency of isolation from ICU versus non-ICU, phenotypic and genotypic profiles in a multinational population of hospitalized patients","volume":"11","author":"Gill","year":"2022","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.lanmic.2026.101364_bib10","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101364_bib11","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3390\/antibiotics11040517","article-title":"Optimizing doses of ceftolozane\/tazobactam as monotherapy or in combination with amikacin to treat carbapenem-resistant Pseudomonas aeruginosa","volume":"11","author":"Nasomsong","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.lanmic.2026.101364_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106887","article-title":"Ceftolozane\/tazobactam plus tobramycin against free-floating and biofilm bacteria of hypermutable Pseudomonas aeruginosa epidemic strains: resistance mechanisms and synergistic activity","volume":"62","author":"Agyeman","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.lanmic.2026.101364_bib13","doi-asserted-by":"crossref","first-page":"9098","DOI":"10.1038\/s41598-019-45550-z","article-title":"Dual \u03b2-lactam combination therapy for multi-drug resistant Pseudomonas aeruginosa infection: enhanced efficacy in vivo and comparison with monotherapies of penicillin-binding protein inhibition","volume":"9","author":"Siriyong","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.lanmic.2026.101364_bib14","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02055-17","article-title":"Optimization of a meropenem-tobramycin combination dosage regimen against hypermutable and nonhypermutable Pseudomonas aeruginosa via mechanism-based modeling and the hollow-fiber infection model","volume":"62","author":"Landersdorfer","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanmic.2026.101364_bib15","first-page":"21","article-title":"Synergism and antagonism in double beta-lactam antibiotic combinations","volume":"80","author":"Gutmann","year":"1986","journal-title":"Am J Med"},{"key":"10.1016\/j.lanmic.2026.101364_bib16","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.3390\/antibiotics11111467","article-title":"Carbapenem-only combination therapy against multi-drug resistant Pseudomonas aeruginosa: assessment of in vitro and in vivo efficacy and mode of action","volume":"11","author":"Mackay","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.lanmic.2026.101364_bib17","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00026-18","article-title":"Evaluation of ceftolozane-tazobactam in combination with meropenem against Pseudomonas aeruginosa sequence type 175 in a hollow-fiber infection model","volume":"62","author":"Montero","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanmic.2026.101364_bib18","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2024"},{"key":"10.1016\/j.lanmic.2026.101364_bib19","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.cmi.2024.06.026","article-title":"The effects of single and multiple resistance mechanisms on bacterial response to meropenem","volume":"30","author":"Fuhs","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.lanmic.2026.101364_bib20","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/jcph.395","article-title":"Population pharmacokinetics of ceftolozane\/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections","volume":"55","author":"Chandorkar","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.lanmic.2026.101364_bib21","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1093\/jac\/dky370","article-title":"Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections","volume":"73","author":"Burger","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.lanmic.2026.101364_bib22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1208\/s12248-011-9257-x","article-title":"Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT","volume":"13","author":"Bulitta","year":"2011","journal-title":"AAPS J"},{"key":"10.1016\/j.lanmic.2026.101364_bib23","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01589-17","article-title":"Genomics and susceptibility profiles of extensively drug-resistant Pseudomonas aeruginosa isolates from Spain","volume":"61","author":"del Barrio-Tofi\u00f1o","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanmic.2026.101364_bib24","article-title":"PBP target profiling by \u03b2-lactam and \u03b2-lactamase inhibitors in intact Pseudomonas aeruginosa: effects of the intrinsic and acquired resistance determinants on the periplasmic drug availability","volume":"11","author":"Montaner","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.lanmic.2026.101364_bib25","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00894-20","article-title":"Adding insult to injury: mechanistic basis for how AmpC mutations allow Pseudomonas aeruginosa to accelerate cephalosporin hydrolysis and evade avibactam","volume":"64","author":"Slater","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanmic.2026.101364_bib26","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.3389\/fmicb.2017.02385","article-title":"Structure-function relationship of aminopeptidase P from Pseudomonas aeruginosa","volume":"8","author":"Peng","year":"2017","journal-title":"Front Microbiol"},{"key":"10.1016\/j.lanmic.2026.101364_bib27","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1128\/AAC.02676-15","article-title":"Evolution of Pseudomonas aeruginosa antimicrobial resistance and fitness under low and high mutation rates","volume":"60","author":"Cabot","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanmic.2026.101364_bib28","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/AAC.02462-13","article-title":"Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC","volume":"58","author":"Cabot","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanmic.2026.101364_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215456","article-title":"Investigation of Pseudomonas aeruginosa strain PcyII-10 variants resisting infection by N4-like phage Ab09 in search for genes involved in phage adsorption","volume":"14","author":"Latino","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.lanmic.2026.101364_bib30","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/cpt.2191","article-title":"Evaluation of meropenem-ciprofloxacin combination dosage regimens for the pharmacokinetics of critically ill patients with augmented renal clearance","volume":"109","author":"Agyeman","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.lanmic.2026.101364_bib31","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00414-23","article-title":"Ceftolozane-tazobactam against Pseudomonas aeruginosa cystic fibrosis clinical isolates in the hollow-fiber infection model: challenges imposed by hypermutability and heteroresistance","volume":"67","author":"Tait","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanmic.2026.101364_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107161","article-title":"Synergistic effects of inhaled aztreonam plus tobramycin on hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic biofilm model evaluated by mechanism-based modelling and whole genome sequencing","volume":"63","author":"Breen","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.lanmic.2026.101364_bib33","doi-asserted-by":"crossref","first-page":"e795","DOI":"10.1016\/S2666-5247(22)00121-5","article-title":"Research priorities towards precision antibiotic therapy to improve patient care","volume":"3","author":"Bulman","year":"2022","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.lanmic.2026.101364_bib34","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/phar.2781","article-title":"Antimicrobial susceptibility testing: an updated primer for clinicians in the era of antimicrobial resistance: insights from the Society of Infectious Diseases Pharmacists","volume":"43","author":"Wenzler","year":"2023","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.lanmic.2026.101364_bib35","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ijantimicag.2016.02.010","article-title":"Impact of multidrug resistance on the pathogenicity of Pseudomonas aeruginosa: in vitro and in vivo studies","volume":"47","author":"G\u00f3mez-Zorrilla","year":"2016","journal-title":"Int J Antimicrob Agents"}],"container-title":["The Lancet Microbe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666524726000194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666524726000194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:23:37Z","timestamp":1788438217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666524726000194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2666524726000194"],"URL":"https:\/\/doi.org\/10.1016\/j.lanmic.2026.101364","relation":{},"ISSN":["2666-5247"],"issn-type":[{"value":"2666-5247","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual \u03b2-lactam therapy against high-risk Pseudomonas aeruginosa isolates: a dynamic in-vitro infection model study integrating population genomics with quantitative systems pharmacology modelling and simulations","name":"articletitle","label":"Article Title"},{"value":"The Lancet Microbe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanmic.2026.101364","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101364"}}